|
293 Companies |
|
490 Products |
|
490 Products |
|
199 Mechanisms of Action |
|
25 Trials |
|
7787 News |
|
| «12...7374757677787980818283...156157» |
- |||||| Actemra IV (tocilizumab) / Roche, JW Pharma, Actemra SC (tocilizumab SC) / Roche, Halozyme
Enrollment open: A Study of the Efficacy and Safety of Tocilizumab in Adults With Rheumatoid Arthritis. (clinicaltrials.gov) - Feb 6, 2015
P3, N=100, Recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Recruiting
- ||| sirolimus / Generic mfg.
Enrollment closed, Trial primary completion date: Prospective Study of Rapamycin for the Treatment of SLE (clinicaltrials.gov) - Feb 6, 2015
P2, N=80, Active, not recruiting, Sponsor: State University of New York - Upstate Medical University
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2013 --> Dec 2015
- | pepinemab (VX15) / Vaccinex
Trial completion, Trial primary completion date: Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS (clinicaltrials.gov) - Feb 6, 2015
P1, N=50, Completed, Sponsor: Vaccinex Inc.
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2013 --> Dec 2015 Active, not recruiting --> Completed | Trial primary completion date: Jun 2015 --> Nov 2014
- ||| Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion: An Global Comparative Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Feb 6, 2015
P=N/A, N=1228, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed | Trial primary completion date: Jun 2015 --> Nov 2014 Recruiting --> Completed
- Trial primary completion date: Single Incision Versus Standard Laparoscopic Splenectomy (clinicaltrials.gov) - Feb 5, 2015
P=N/A, N=30, Recruiting, Sponsor: Children's Mercy Hospital Kansas City
Recruiting --> Completed Trial primary completion date: Oct 2013 --> Oct 2016
- || Humira (adalimumab) / Eisai, AbbVie
Trial initiation date, Trial primary completion date: ORIENT: Real Life Evaluation of Rheumatoid Arthritis Patients in Israel Treated With HUMIRA (clinicaltrials.gov) - Feb 5, 2015
P=N/A, N=100, Not yet recruiting, Sponsor: AbbVie
Trial primary completion date: Oct 2013 --> Oct 2016 Initiation date: Dec 2014 --> Mar 2015 | Trial primary completion date: Dec 2018 --> Mar 2019
- Orencia (abatacept) / BMS
P2 data, Enrollment change, Trial withdrawal: Abatacept for Patients With Inflammatory Arthritis Associated With Sjögren's Syndrome: an Open-Label Phase II Study (clinicaltrials.gov) - Feb 5, 2015
P2, N=0, Withdrawn, Sponsor: Qingping Yao
Initiation date: Dec 2014 --> Mar 2015 | Trial primary completion date: Dec 2018 --> Mar 2019 N=15 --> 0 | Recruiting --> Withdrawn
- amiloride hydrochloride / Generic mfg.
Enrollment closed, Trial primary completion date: ACTION: Amiloride Clinical Trial In Optic Neuritis (clinicaltrials.gov) - Feb 5, 2015
P2, N=46, Active, not recruiting, Sponsor: University of Oxford
N=15 --> 0 | Recruiting --> Withdrawn Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2014 --> Nov 2015
- dalfampridine / Generic mfg.
Trial completion: Observational Study for Assessment of the Effect of Fampyra on the Manual Function of Persons With Multiple Sclerosis (clinicaltrials.gov) - Feb 5, 2015
P=N/A, N=47, Completed, Sponsor: Carmel Medical Center
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2014 --> Nov 2015 Recruiting --> Completed
- Trial completion, Enrollment change, Trial primary completion date, IO biomarker: Nanotechnology for Detection of Multiple Sclerosis Compared to Autoimmune and Neurological Diseases by Exhaled Samples (clinicaltrials.gov) - Feb 5, 2015
P1, N=314, Completed, Sponsor: Carmel Medical Center
Recruiting --> Completed Recruiting --> Completed | N=400 --> 314 | Trial primary completion date: Dec 2014 --> Feb 2014
- Trial completion, Enrollment change, Trial primary completion date: MS-NANOSE: Applications of Nanotechnology in Multiple Sclerosis by Respiratory Samples (clinicaltrials.gov) - Feb 5, 2015
P1, N=71, Completed, Sponsor: Carmel Medical Center
Recruiting --> Completed | N=400 --> 314 | Trial primary completion date: Dec 2014 --> Feb 2014 Active, not recruiting --> Completed | N=100 --> 71 | Trial primary completion date: Aug 2015 --> Nov 2011
- Tresiba (insulin degludec) / Novo Nordisk
Trial initiation date, Trial primary completion date: A Non-interventional, Post Marketing Surveillance (PMS) Study of Tresiba (clinicaltrials.gov) - Feb 5, 2015
P=N/A, N=1000, Not yet recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed | N=100 --> 71 | Trial primary completion date: Aug 2015 --> Nov 2011 Initiation date: Dec 2014 --> Mar 2015 | Trial primary completion date: Dec 2016 --> Mar 2017
- || Enrollment closed, Trial primary completion date: E3: Adult Accuracy Study of the Enlite 3 Glucose Sensor (clinicaltrials.gov) - Feb 5, 2015
P=N/A, N=100, Active, not recruiting, Sponsor: Medtronic Diabetes
Initiation date: Dec 2014 --> Mar 2015 | Trial primary completion date: Dec 2016 --> Mar 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2014 --> Jul 2015
- Trial completion, Trial primary completion date: Low Fat Diet and Multiple Sclerosis (clinicaltrials.gov) - Feb 5, 2015
P1, N=61, Completed, Sponsor: Oregon Health and Science University
Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2014 --> Jul 2015 Active, not recruiting --> Completed | Trial primary completion date: Mar 2013 --> Jul 2014
- Trial primary completion date: ANSG: Evaluation of the Autonomic Nervous System During First-dosing With 0.5mg of Fingolimod (Gilenya) in Patients With Relapsing-remitting MS (clinicaltrials.gov) - Feb 3, 2015
P4, N=30, Recruiting, Sponsor: Jochen Vehoff
Active, not recruiting --> Completed | Trial primary completion date: Mar 2013 --> Jul 2014 Trial primary completion date: Aug 2014 --> Jun 2015
- |||| tabalumab (LY2127399) / Eli Lilly
Trial primary completion date: Illuminate-Xt: On Open-Label Study in Participants With Systemic Lupus Erythematosus (clinicaltrials.gov) - Feb 3, 2015
P3, N=1276, Active, not recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: Aug 2014 --> Jun 2015 Trial primary completion date: Jan 2015 --> Dec 2015
- || Orencia (abatacept) / BMS
Trial initiation date, Trial primary completion date: Safety Study of Abatacept to Treat Rheumatoid Arthritis (B) (clinicaltrials.gov) - Feb 3, 2015
P=N/A, N=20000, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Jan 2015 --> Dec 2015 Initiation date: Oct 2006 --> Mar 2005 | Trial primary completion date: Jan 2015 --> Mar 2017
- || Orencia (abatacept) / BMS
Trial initiation date: Safety Study of Abatacept to Treat Rheumatoid Arthritis (A) (clinicaltrials.gov) - Feb 3, 2015
P=N/A, N=40000, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Initiation date: Oct 2006 --> Mar 2005 | Trial primary completion date: Jan 2015 --> Mar 2017 Initiation date: Jun 2007 --> Mar 2005
- | Enrollment closed: WebSMART: Efficacy of Web-based Pain Self-management for Adolescents With Juvenile Idiopathic Arthritis (clinicaltrials.gov) - Feb 3, 2015
P3, N=360, Active, not recruiting, Sponsor: Children's Mercy Hospital Kansas City
Initiation date: Jun 2007 --> Mar 2005 Recruiting --> Active, not recruiting
- || Trial primary completion date: BIOFLOW III Asia Registry Orsiro Stent System (clinicaltrials.gov) - Feb 3, 2015
P=N/A, N=880, Recruiting, Sponsor: BIOTRONIK Asia Pacific Pte Ltd
Recruiting --> Active, not recruiting Trial primary completion date: Sep 2014 --> Sep 2015
- || Enrollment closed: CGM Treatment in Patients With Type 1 Diabetes Treated With Insulin Injections (clinicaltrials.gov) - Feb 3, 2015
P=N/A, N=120, Active, not recruiting, Sponsor: Vastra Gotaland Region
Trial primary completion date: Sep 2014 --> Sep 2015 Recruiting --> Active, not recruiting
- || Enrollment closed, Trial primary completion date: BIOFLOW-III Israel Satellite Registry (clinicaltrials.gov) - Feb 3, 2015
P=N/A, N=120, Active, not recruiting, Sponsor: BIOTRONIK Israel
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2015 --> May 2014
- Trial completion: Effects of Vitamin C and E on Endothelial Function in Adolescent Diabetes (clinicaltrials.gov) - Feb 3, 2015
P4, N=9, Completed, Sponsor: Nationwide Children's Hospital
Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2015 --> May 2014 Recruiting --> Completed
- |||| Enbrel (etanercept) / Pfizer, Amgen
Trial completion: ANTIBODY-RA: Drug Concentration, Immunogenicity, and Efficacy Study in Patients With Rheumatoid Arthritis Currently Treated With Etanercept, Adalimumab, or Infliximab (clinicaltrials.gov) - Feb 3, 2015
P4, N=629, Completed, Sponsor: Pfizer
Recruiting --> Completed Recruiting --> Completed
- Rebif (human IFN-?-1a) / EMD Serono
Trial termination, Trial primary completion date, Adherence: EMR 200136-567: Adherence Trial With MS LifeLines (clinicaltrials.gov) - Feb 2, 2015
P=N/A, N=306, Terminated, Sponsor: EMD Serono
Recruiting --> Completed Active, not recruiting --> Terminated | Trial primary completion date: Jul 2015 --> Jan 2015; The study was terminated as per the Sponsor's decision.
- Cimzia (certolizumab pegol) / Astellas, UCB
Phase classification: CRADLE: A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers (clinicaltrials.gov) - Feb 2, 2015
P1, N=16, Recruiting, Sponsor: UCB BIOSCIENCES, Inc.
Active, not recruiting --> Terminated | Trial primary completion date: Jul 2015 --> Jan 2015; The study was terminated as per the Sponsor's decision. Phase classification: P1b --> P1
- |||||| Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
Enrollment open: RA-COMPARE: An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate (clinicaltrials.gov) - Feb 2, 2015
P3, N=700, Recruiting, Sponsor: Sanofi
Phase classification: P1b --> P1 Active, not recruiting --> Recruiting
- ||||| AcellBia (rituximab biosimilar) / Biocad, Kocak Farma
Enrollment closed, Enrollment change: BIORA: Study of Safety and Efficacy of BCD-020 Comparing to MabThera in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Feb 2, 2015
P3, N=160, Active, not recruiting, Sponsor: Biocad
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting | N=308 --> 160
- | Plegridy (PEG-interferon ?-1a) / Biogen
Trial completion: Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif (clinicaltrials.gov) - Feb 2, 2015
P1, N=30, Completed, Sponsor: Biogen Idec
Recruiting --> Active, not recruiting | N=308 --> 160 Recruiting --> Completed
- bortezomib / Generic mfg.
Trial primary completion date: Pilot Study of Velcade® in IgA Nephropathy (clinicaltrials.gov) - Jan 30, 2015
P4, N=10, Recruiting, Sponsor: The Rogosin Institute
Recruiting --> Completed Trial primary completion date: Jul 2015 --> Jul 2016
- ||| remtolumab (ABT-122) / AbbVie
P2 data, Trial initiation date: A Phase 2 Study to Investigate the Safety and Efficacy of ABT-122 Given With Methotrexate in Subjects With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate (clinicaltrials.gov) - Jan 30, 2015
P2, N=160, Recruiting, Sponsor: AbbVie
Trial primary completion date: Jul 2015 --> Jul 2016 Initiation date: Jun 2014 --> Jan 2014
- Clinical: Rheumatoid Arthritis Through Education and US Study (RAEUS) (clinicaltrials.gov) - Jan 30, 2015
P=N/A, N=101, Completed, Sponsor: National University Hospital, Singapore
- ||| Clinical: A Post-Marketing Observational Study to Evaluate Primus™ FGT Implant at a Minimum of 5 Years Follow-up (clinicaltrials.gov) - Jan 30, 2015
P=N/A, N=70, Completed, Sponsor: Tornier
- hydroxychloroquine / Generic mfg.
New P4 trial: Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy: a Self- Controlled Study (clinicaltrials.gov) - Jan 30, 2015
P4, N=20, Recruiting, Sponsor: LLiu
- || Venclexta (venetoclax) / Roche, AbbVie
Trial primary completion date: A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE) (clinicaltrials.gov) - Jan 30, 2015
P1, N=88, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Initiation date: Jun 2014 --> Jan 2014 Trial primary completion date: Dec 2014 --> Jul 2015
- || dexamethasone / Generic mfg.
New P3 trial: Caffeic Acid Tablets as a Second-line Therapy for ITP (clinicaltrials.gov) - Jan 30, 2015
P3, N=200, Recruiting, Sponsor: Shandong University
- |||| BI 695500 (rituximab biosimilar) / Boehringer Ingelheim
Trial primary completion date: Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Jan 29, 2015
P3, N=306, Recruiting, Sponsor: Boehringer Ingelheim
Trial primary completion date: Dec 2014 --> Jul 2015 Trial primary completion date: Aug 2015 --> Jan 2015
- |||| vatelizumab (GBR 500) / Glenmark
Enrollment open: Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839 (clinicaltrials.gov) - Jan 29, 2015
P2, N=168, Recruiting, Sponsor: Genzyme, a Sanofi Company
Trial primary completion date: Aug 2015 --> Jan 2015 Not yet recruiting --> Recruiting
- Novolin R (recombinant human insulin) / Novo Nordisk
Trial primary completion date: Pilot Study Investigating the Feasibility of Determining the Endogenous Glucose Production During a Hypoglycaemia (clinicaltrials.gov) - Jan 29, 2015
P2, N=20, Enrolling by invitation, Sponsor: Medical University of Graz
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2014 --> Mar 2015
- Clinical: Carbohydrate Counting in Children and Adolescents With Type 1 Diabetes (clinicaltrials.gov) - Jan 29, 2015
P=N/A, N=80, Recruiting, Sponsor: Fondation Lenval
- | New P1 trial: A Study to Assess Inflammation in Rheumatoid Arthritis Using Molecular Imaging Techniques (clinicaltrials.gov) - Jan 29, 2015
P1, N=20, Not yet recruiting, Sponsor: GlaxoSmithKline
- INV103 / Invion
Trial primary completion date: Double-Blinded, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Biochemical Activity of Intravenous Cpn10 Administration in Subjects With Mild to Moderate SLE. (clinicaltrials.gov) - Jan 28, 2015
P1/2, N=40, Recruiting, Sponsor: Invion, Inc.
Trial primary completion date: Dec 2014 --> Mar 2015 Trial primary completion date: Dec 2014 --> Mar 2015
- || New P3 trial: Project JAY THA Registration Study (clinicaltrials.gov) - Jan 28, 2015
P3, N=96, Not yet recruiting, Sponsor: Smith & Nephew Orthopaedics (Beijing) Limited
- ||| Humira (adalimumab) / Eisai, AbbVie
Enrollment closed, Trial primary completion date: RADAR: A Canadian Study to Evaluate Early Use of Adalimumab After Methotrexate Failure in Early Rheumatoid Arthritis (clinicaltrials.gov) - Jan 28, 2015
P4, N=320, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Trial primary completion date: Dec 2014 --> Mar 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2021 --> Jul 2015
- | Trial completion, Enrollment change, Trial primary completion date: Treatment of Upper Eyelid Retraction Related to Thyroid-associated Ophthalmopathy Using Subconjunctival Triamcinolone Injections (clinicaltrials.gov) - Jan 28, 2015
P4, N=50, Completed, Sponsor: Yonsei University
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2021 --> Jul 2015 Recruiting --> Completed | N=100 --> 50 | Trial primary completion date: Jul 2012 --> Aug 2014
- Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion, HEOR: RA-PROACTIVE: Long Term Effects of an Early Response to Certolizumab Pegol (CZP, Cimzia®) in Rheumatoid Arthritis (RA) Patients (clinicaltrials.gov) - Jan 28, 2015
P=N/A, N=152, Completed, Sponsor: UCB Pharma
Recruiting --> Completed | N=100 --> 50 | Trial primary completion date: Jul 2012 --> Aug 2014 Active, not recruiting --> Completed
- Trial primary completion date: Continuous Correction (clinicaltrials.gov) - Jan 28, 2015
P=N/A, N=12, Recruiting, Sponsor: Hvidovre University Hospital
Active, not recruiting --> Completed Trial primary completion date: Jun 2015 --> Jun 2016
- Trial primary completion date: Overnight MD-Logic (clinicaltrials.gov) - Jan 28, 2015
P=N/A, N=263, Recruiting, Sponsor: Rabin Medical Center
Trial primary completion date: Jun 2015 --> Jun 2016 Trial primary completion date: Dec 2015 --> Dec 2016
- Trial termination, Trial primary completion date: A Clinical Investigation of the M2a-Magnum (clinicaltrials.gov) - Jan 28, 2015
P=N/A, N=249, Terminated, Sponsor: Biomet Orthopedics, LLC
Trial primary completion date: Dec 2015 --> Dec 2016 Active, not recruiting --> Terminated | Trial primary completion date: Nov 2018 --> Jan 2015; Centers would not continue follow-up; two centers transitioned patients to a new study.
- ||| HEOR: Factors Associated With Biologic DMARD Switching (clinicaltrials.gov) - Jan 28, 2015
P=N/A, N=4099, Active, not recruiting, Sponsor: Bristol-Myers Squibb